Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?
4 Dec 2018 9:30 – 11:00 am
The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.[/vc_column_text][vc_column_text]They will share their experience:
- Jan Adams, Managing Director, EMBL Ventures (DE)
- Jonathan Tobin, Investment Director, Arix Bioscience (UK)
|
